Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis

BACKGROUND: One year of adjuvant trastuzumab in combination with chemotherapy is the standard of care in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Existing data on shortening trastuzumab treatment show conflicting results. METHODS: A search of PubMed and abs...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JNCI Cancer Spectr
Hlavní autoři: Goldvaser, Hadar, Korzets, Yasmin, Shepshelovich, Daniel, Yerushalmi, Rinat, Sarfaty, Michal, Ribnikar, Domen, Thavendiranathan, Paaladinesh, Amir, Eitan
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Meta-Analysis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6649709/
https://ncbi.nlm.nih.gov/pubmed/31360906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkz033
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky